Haematology, Oncology and Palliative Care Directorate.

Similar documents
Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Emetogenicity level 1. Emetogenicity level 2

Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference

Working Formulary January 2013 Oncology Chemotherapy Regimens

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Guidelines for the Use of Anti-Emetics with Chemotherapy

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

CCC Chemotherapy Protocols V9.0

The AngCN Antiemetic Guidelines

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

To help doctors give their patients the best possible care, the American

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

Standard Regimens for Haematology

MASCC Guidelines for Antiemetic control: An update

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Guideline Update on Antiemetics

1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8

Antiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy

MEDICAL NECESSITY GUIDELINE

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK

Northern Cancer Alliance

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Part B payment for drugs in Medicare 0

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines


SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

Part B payment for drugs in Medicare 0

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Guidelines for the Management of Extravasation (Version 5 May 2012)

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Managements of Chemotherpay Induded Nausea and Vomiting

Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto

OPCS Classification of Interventions and Procedures Version 4.6 (April 2011)

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma

General Authorization Criteria for ALL Agents and Indications:

Subject: Palonosetron Hydrochloride (Aloxi )

Guidelines for the Management of Extravasation

Chapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline

Guidelines for prevention and management of CHEMOTHERAPY EXTRAVASATION

Disease Site Sub-Disease Site Intent Regimen Code Regimen Details Status (as of October 17, 2017) Breast Not Applicable Adjuvant / Curative

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Pharmacy Prior Authorization Colony Stimulating Factors Clinical Guideline. Neulasta Onpro (peg-filgrastim; G-CSF) Leukine (sargramostim; GM-CSF)

CHEMOTHERAPY NETWORK GROUP POLICY FOR THE MANAGEMENT

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes. Lorenzo Moja

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Trust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Cancer drug approvals for paediatric indications (n=43)

Contents Trials. Dose guidelines. Calvert formula Issue Date: January Author: No: Copy. Pagee 1 of 21. Issue.

National Cancer Drugs Fund List - Approved

Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment

Acute Lymphocytic Leukemia

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Vasco OP Underglove Sterile Surgical and Protective Gloves

CancerPACT Cancer Patients Alliance for Clinical Trials

For Health Professionals Who Care For Cancer Patients

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Bladder Cancer (Urothelial) Pathways

Transitioning Inpatient Chemotherapy to the Outpatient Setting

See Important Reminder at the end of this policy for important regulatory and legal information.

TRANSPARENCY COMMITTEE OPINION. 29 April 2009

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

TRANSPARENCY COMMITTEE OPINION. 15 February 2006

DRUG EXTRAVASATION. Vesicants. Irritants

Bladder Cancer Pathways (Urothelial)

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

For Health Professionals Who Care For Cancer Patients

Title Developed By. Implementation Contact person(s) Review Date Group Responsible. NICaN Policy: Management of Chemotherapy Extravasation; Version 3

Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients

亞東紀念醫院 Breast Cancer 化學治療處方集

Chemotherapy 101 for Radiation Oncology Workers

Patient 1: Patient 2:

ST-QBP: Systemic Treatment Quality-Based Program (formerly STFM) DF: Drug Formulary GYNECOLOGICAL SKIN HEMATOLOGY ST- QBP

NEW DRUG FUNDING PROGRAM (NDFP) & EVIDENCE BUILDING PROGRAM (EBP) Approved Drugs and Eligibility Criteria

Transcription:

Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile Chemotherapy Unit. Treatment from the appropriate cycle is indicated with suitability This list should be used as a guideline and the suitability of different regimens must also be based on the patient s Performance Status, suitability for treatment and demographics as well as whether treatment can feasibly be administered on an appropriate day. Any patient who has requested use of the scalp cooler will need to be treated at MPH. COLOUR KEY SUITABLE RESTRICTED INDIVIDUAL PATIENT BASIS NOT SUITABLE BRAIN CANCER BREAST CANCER Abraxane/Gemcitabine 8 hour expiry on Abraxane, difficult to make up 2 1 hour 30 mins Carboplatin (Single Agent) 3 weekly 3 1 hour 30 mins Carboplatin (Single Agent) - weekly 3 Docetaxel (Taxotere ) 3-weekly 3 1 hour 30 mins Docetaxel (Taxotere ) weekly 3 1 hour 30 mins EC 2 1 hour 30 mins Epirubicin (Single Agent) 3-weekly 2 1 hour Epirubicin (Single Agent) weekly 2 1 hour Eribulin 2 4 mins FEC 2 2 hours Paclitaxel + Cyclophosphamide (TC) Paclitaxel (Taxol equiv.) 3-weekly Paclitaxel (Taxol equiv.) weekly 3 2 hours Paclitaxel Albumin (Abraxane ) Drug only has an 8-hour expiry Pamidronate 2 For 1 or 2 hour infusion only (30mg 4 mins, 90mg 2 hours) Trastuzumab (Herceptin ) IV need to be given in the morning. Alternatively vials 2 could be made up on the bus using an aseptic technique (1 hour) Trastuzumab (Herceptin ) SC 2 30 mins Trastuzumab (Herceptin ) + Docetaxel 3 need to be given in the morning. (1hour 30 mins) Trastuzumab (Herceptin ) + Docetaxel + 3 Peruzumab need to be given in the morning. (3hours) Trastuzumab (Herceptin ) + Pertuzumab 3 need to be given in the morning. (3hours) Kadcyla 3 Vinorelbine 2 need to be given in the morning (4 mins) Zoledronate 2 30 mins COLORECTAL CANCER 2 1 Page 1 of

-FU (-Fluorouracil) bolus 2 4 mins -FU pump change + Capecitabine 2 + Irinotecan + Capecitabine Cetuximab + Oxaliplatin + Capecitabine Cetuximab + Oxaliplatin + MdG Irinotecan Irinotecan + MdG (FOLFIRI) Irinotecan + MdG (FOLFIRI) + Cetuximab + Irinotecan + MdG Mitomycin-C + Capecitabine 2 need to be given in the morning. (4mins) Mitomycin-C & -FU Infusion Mod de Gramont (MdG) 2 3 hours Oxaliplatin + Capecitabine (XELOX) Oxaliplatin + Capecitabine (XELOX) + Oxaliplatin + MdG (FOLFOX) Oxaliplatin + MdG (FOLFOX) + Panitumumab 3 2hours 30 mins GYNAECOLOGICAL CANCER Carboplatin 3 1 hour 30 mins Carboplatin & Gemcitabine 3 Suitable from #2 Day 8 (2hours) Carboplatin & Paclitaxel (Taxol) Cisplatin Cisplatin + Doxorubicin (MMMT) Cisplatin + -FU (4 days) Cisplatin + Topotecan Doxorubicin Liposomal (Caelyx ) Only has a 24hr expiry Gemcitabine (Day 8) 2 1 hour Paclitaxel (Taxol equiv.) 3-weekly Paclitaxel (Taxol equiv.) weekly 3 2 hours HAEMATOLOGICAL DISORDERS Venofer 3 2 hours Vincristine (single agent) IV Infusion (ITP) 2 4 mins HEAD & NECK CANCER Cisplatin, Doxorubicin & -FU (TPF) Docetaxel 3 1 hour 30 mins Cisplatin + -FU ( 4 / 7 ) IMMUNOGLOBULINS Flebogammadif 3 Prolonged infusion but possible to be given on bus (4 hours) Privagen 3 Prolonged infusion but possible to be given on bus (4 hours) Vigam Impractical to give on bus as infusion is given slower than other IVIGs LEUKAEMIA ADE Alemtuzumab (MabThera ) Arsenic Trioxide Azacytidine Drug only has a 24-hour expiry, cold chain must be maintained Cladribine Day 3 Difficult as Treatment is given over or 7 days 2 1 Page 2 of

(2 hours 30 mins) Cytarabine IV 2 2 hours Cytarabine Subcutaneous 2 30 mins Daunorubicin + Clofarabine Daunorubicin + Cytarabine (DA) FC (IV) 2 Difficult as Treatment is given over 3 or days FLA(G) FLA-IDA Fludarabine (IV) Days 1- Day 3 Difficult as Treatment is given over 3 or days Intrathecal Methotrexate / Cytarabine MACE MCP 2 4 mins MiDAC Vincristine (single agent) IV bolus 3 4 mins LUNG CANCER & MESOTHELIOMA Carboplatin (iv) + Etoposide (po) 3 2 hours 30 mins Carboplatin + Gemcitabine 3 2 hours Carboplatin + Pemetrexed (Alimta ) 3 need to be given in the morning. (2hours) Carboplatin + Vinorelbine 3 need to be given in the morning. (2hour 30mins) Cisplatin + Etoposide Cisplatin + Pemetrexed (Alimta ) Cisplatin + Vinorelbine Docetaxel (Taxotere ) 3 1 hour 30 mins Etoposide IV 2 1 hour 1 mins Pamidronate 2 (30mg 4 mins, 90mg 2 hours) Paclitaxel + Gemcitabine Paclitaxel + Pemetrexed (Alimta ) Pemetrexed only has a 24hr expiry Pemetrexed 2 Refer to Healthcare@Home if patient agrees (1 hour) Vinorelbine 2 need to be given in the morning (4 mins) Zolendronate 2 30 mins LYMPHOMA ABVD Not recommended as dacarbazine only has a 24hr expiry and is usually made on day of infusion in view of risk of reaction. BEAM Bendamustine 2 ChlVEP 2 1 hour ChlVPP 2 1 hour CNOP 2 CHOP 2 CODOX-M Difficult as Treatment is given over 2 days although should be possible to administer on a (1 hour 30 mins) 2 1 Page 3 of

COP / CVP 2 Cyclophosphamide PBSC DHAP FC (Fludaradine + Cyclophosphamide) IV 2 Fludarabine (IV) 2 FMD (IV) 2 FMD (po) 2 Gemcitabine 2 1 hour Intrathecal Methotrexate / Cytarabine 2 Difficult as Treatment is given over 3 or days Difficult as Treatment is given over days although should be possible to administer on a IVAC MCP / MCD 2 Methylprednisolone IV Stat 2 1 hour Pixantrone 2 R-CEP 3 3 hours 1 mins R-CHOP 3 3 hours 30 mins R-CNOP 3 3 hours 1 mins R-CODOX-M R-CVP 3 3 hours 1 mins R-DHAP R-FC (Fludaradine + Cyclophosphamide) PO 3 3 hours 1 mins R-FC (Fludaradine + Cyclophosphamide) IV Day 2 Difficult as Treatment is given over 3 or days R-MCP 3 3 hours 1 mins Rituximab (single agent) IV 3 3 hours Rituximab SC 3 30 mins (maintenance Ritux to be referred to Healthcare at home if patient agrees) R-MCP 3 3 hours 1 mins MULTIPLE MYELOMA Bortezomib (Velcade ) - Weekly 2 need to be given in the morning. Refer to Healthcare@Home if patient agrees (30 mins) Bortezomib (Velcade ) D1,4,8 & 11 2 Refer to Healthcare@Home if patient agrees. Drug only has a 24-hour expiry so treatment would need to be given in the morning. Caution if having on MCU some doses will need to be given in BDU (30 mins) Melphalan IV Expiry of drug only 2-3 hours Pamidronate 2 (30mg 4 mins, 90mg 2 hours) Zolendronate 2 30 mins RENAL CELL CARCINOMA SARCOMA Cisplatin + Doxorubicin Docetaxel (Taxotere ) + Gemcitabine 3 Doxorubicin (Single Agent) 2 1 hour SKIN CANCER CVD (Cisplatin, Vinblastine & Docetaxel) Dacarbazine (DTIC) Ipilimumab Pembrolizumab 1 Page 4 of

Vinblastine Weekly 2 UPPER GASTROINTESTINAL CANCER Abraxane/Gemcitabine Abraxane 8 hour expiry, difficult to make up Cetuximab 2 3 hours Cisplatin + -FU (4-day infusion) Cisplatin + -FU (Continuous) Docetaxel, Cisplatin and -Fluorouracil (TPF) ECarboF 3 Possible with walkmed infusor (2hours) ECisF ECX ECX + Gemcitabine 2 1 hour Octreotide LAR 2 Ranucirumab 2 need to be given in the morning. (2 hours 30 mins) UNKNOWN PRIMARY UROLOGICAL CANCER Cabazitaxel 3 CarboGem 3 Can be given #2 Day 8 (2hours) CarboMV 3 CisMV Cisplatin + -FU ( 4 / 7 ) Docetaxel (Taxotere ) + Prednisolone 3 Mitoxantrone + Prednisolone 2 4 mins Pamidronate 2 Zolendronate 2 2 1 Page of